Neurocrine Biosciences (NBIX) highlighted its expanding commercial footprint and robust pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. The company, which reported approximately $1 billion in sales in the most recent quarter, reaffirmed its 2025 revenue guidance at $2.85 billion—a 13% year-over-year increase. Trailing twelve-month revenue stood at $3.37 billion, reflecting a 34% growth rate, underscoring sustained momentum in its drug portfolio. With a financial health score of 3.57 out of 5 and a return on assets of 15%, NBIX maintains strong operational metrics, supported by a P/E ratio of 22.63 and a PEG ratio of 0.22, as per InvestingPro data. The stock traded at $155.14 at the time of the presentation.
The company’s growth strategy centers on three key products, each contributing to its expanding revenue base. INGREZZA, Neurocrine’s flagship drug for tardive dyskinesia, remains protected through 2038, with a U.S. patient population estimated at 800,000—about 400,000 of whom are formally diagnosed. Despite pricing pressures from Medicare’s Inflation Reduction Act (IRA), formulary access has improved from 30% in 2024 to 70% in 2025, with rebates expected to rise to 8% by 2028. While the IRA’s 2029 negotiation could introduce a 25%–34% discount, the brand is projected to remain profitable through offsets like voluntary rebates and formulary agreements.
CRENESSITY, approved for congenital adrenal hyperplasia, has achieved about 15% penetration of its target patient population, benefiting from steady quarter-over-quarter growth and high patient tolerability. VYKAT XR, acquired in May 2025 for Prader-Willi syndrome hyperphagia, is now in its fifth commercial quarter, targeting roughly 10,000 patients. Management anticipates it will become a blockbuster, with plans to expand clinical trials to assess cardiovascular risk and patient selection.
Pipeline expansion has accelerated, growing from three programs five years ago to nearly 20 across psychiatry, neurology, immunology, and endocrinology. Key late-stage candidates include Osavampator (AMPA potentiator for major depressive disorder, with Phase III data due in 2027) and Direclidine (schizophrenia treatment, Phase III in 2028). Additionally, NBI-890, a follow-on VMAT2 molecule in oral and long-acting injectable forms, aims to address patients with poor oral compliance.
Chief Financial Officer Matt Abernethy emphasized the company’s transformation from a single-product to a multi-product entity, citing durable top-line growth, cash flow, and an expanding R&D engine. ‘We are in the fourth or fifth inning of INGREZZA’s lifecycle,’ he noted, highlighting its long-term runway. Eric Benevich, Chief Commercial Officer, framed the company’s progress as a strategic advantage, with commercial expansion in INGREZZA’s prescriber base growing by 30% over the prior two years.
Neurocrine’s strategy balances near-term commercial success with long-term innovation, positioning it for sustained growth in a competitive biopharmaceutical landscape.
